Ceryvyn Therapeutics Ltd
UKJ2
Company Profile
Business description
Ceryvyn Therapeutics Ltd is an Australian biotechnology company developing a biologic therapy for the rare disease LAM (lymphangioleiomyomatosis). It is engaged in the investigation of CYV-101 as a potential treatment for Lymphangioleiomyomatosis (LAM). It operates in one segment, being the biotechnology and healthcare industry in Australia.
Contact
c/-Bio101 Financial Advisory Pty Ltd
Suite 1.01, 117 Camberwell Road
Hawthorn East
MelbourneVIC3123
AUST: +61 398260399
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
10
Stocks News & Analysis
stocks
The best global tech stocks to buy
These 12 undervalued technology stocks look attractive today.
stocks
Earnings margins to improve for mining specialist
Premium products drive margins yet shares fully valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,141.20 | 52.60 | -0.57% |
| CAC 40 | 8,306.15 | 27.38 | 0.33% |
| DAX 40 | 26,006.53 | 39.87 | -0.15% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,822.13 | 8.96 | -0.08% |
| HKSE | 25,413.12 | 237.75 | -0.93% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 66,649.33 | 249.48 | 0.38% |
| NZX 50 Index | 13,916.19 | 26.64 | -0.19% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 8,949.50 | 53.50 | -0.59% |
| SSE Composite Index | 3,932.70 | 2.58 | 0.07% |